Vitae Pharmaceuticals is focused on discovering and developing novel, small molecule, best-in-class compounds that address significant unmet medical needs. Vitae Pharmaceuticals’ robust and growing pipeline of programs was developed through integrating a proprietary, SBDD platform with the experience and insights of a world-class R&D team to enhance the novelty, speed and efficiency of small molecule discovery and development.
VTP-43742, an RORɣt inhibitor and one of several wholly-owned products advancing in preclinical studies, is expected to begin Phase 1 clinical trials in the first half of 2015 as a potential treatment for psoriasis, multiple sclerosis, and other autoimmune disorders. Other products in the pipeline are:
In addition to Vitae Pharmaceuticals’ existing product candidates, the company’s team of scientists is currently utilizing Contour® in their new discovery program in immuno-oncology.